Here, levels of amyloid-β peptides (Aβ1-42), the presence of Tau phosphorylated at a certain residue (P-Tau181), or the total Tau presence in the CSF are routinely monitored in the clinical evaluation of AD [145]. This evidence concerns the gene MAPT and Alzheimer disease.